Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer. Thus, fibroblast growth factor receptors (FGFRs) present promising targets f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Cancer
Päätekijät: Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Cancer Therapy and Prevention
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766871/
https://ncbi.nlm.nih.gov/pubmed/30807645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32224
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia